Sign inJoin free

Watch / Small Cap

Compumedics smashes sales order records

22 Jan 20268:15

Compumedics smashes sales order records

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Record sales orders close to $35 million and 32% growth in shipment revenue for Compumedics (ASX:CMP)

  • Expansion in SaaS home sleep services and soon-to-launch disposable Somfit device targeting new markets

  • Commercialisation of MEG brain imaging systems delivers significant revenue in early years

  • Strategic relationships with ResMed (ASX:RMD), Philips, and a dominant share in Australian pharmacy chains for sleep solutions

  • Positive outlook for US market growth, supported by increased investment in sales and marketing

Compumedics (ASX:CMP) has reported record sales orders nearing $35 million for the half year, with executive chairman Dr David Burton highlighting a 32% increase in shipped revenue for the December period. Burton states the company’s momentum remains strong, driven by renewed focus on commercial execution and a robust pipeline in both its core and emerging product divisions. Attention is now on delivering an even stronger second half, underpinned by continued order growth and delivery performance.

Burton outlines Compumedics’ global leadership in sleep and neurodiagnostic equipment, noting ongoing expansion into web-based SaaS home sleep services through its Somfit device. The upcoming launch of a disposable Somfit product, aimed at capitalising on the large disposable sleep-testing market, is flagged as a major growth catalyst. Additionally, the commercialisation of the company’s MEG brain imaging systems has resulted in approximately $25 million in revenue in the initial years, signalling further potential in this domain.

Major industry players such as ResMed (ASX:RMD) and Philips are noted as key customers, with Compumedics securing roughly 75% of the Australian pharmacy chain market for sleep services. Burton expresses confidence in further expansion, particularly in the US, with new investments and management strengthening the sales and marketing front. The company’s funding and balance sheet are described as solid, aided by the commercial returns from substantial R&D investments.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy